{"id":"ecteinascidin-743","phase":"phase_1","safety":{"boxedWarning":"Hepatotoxicity, rhabdomyolysis, neutropenic sepsis, and extravasation resulting in tissue necrosis requiring debridement have been reported.","boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":["Neutropenia","Thrombocytopenia","Nausea","Fatigue","Elevated liver enzymes","Vomiting"],"contraindications":["Severe hepatic impairment","Hypersensitivity to trabectedin"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT00006463"],"aliases":["ET-743","NSC S648766","IND 50,286"],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"ECTEINASCIDIN 743","companyId":"children-s-oncology-group","mechanism":{"target":"DNA minor groove","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Ecteinascidin 743 alkylates DNA at the N2 position of guanine in the minor groove, bending the helix toward the major groove. This triggers a cascade of events affecting DNA binding proteins and nucleotide excision repair pathways, ultimately leading to cell cycle arrest and apoptosis.","oneSentence":"Binds to the minor groove of DNA, causing DNA strand breaks and disrupting DNA repair mechanisms and transcription.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123475,"model":"claude-sonnet-4-5-20250929"},"companyName":"Children's Oncology Group","competitors":[{"name":"doxorubicin","brand":"Adriamycin","company":null,"rationale":"First-line anthracycline for soft tissue sarcomas"},{"name":"pazopanib","brand":"Votrient","company":"Novartis","rationale":"Approved for advanced soft tissue sarcoma after chemotherapy"},{"name":"eribulin","brand":"Halaven","company":"Eisai","rationale":"Approved for liposarcoma after anthracycline-based therapy"}],"description":"Ecteinascidin 743 (ET-743, trabectedin) is a marine-derived antineoplastic agent originally isolated from the Caribbean sea squirt Ecteinascidia turbinata. It is being investigated by the Children's Oncology Group in phase 1 trials for pediatric cancers, with established use in soft tissue sarcomas in adults.","genericName":"ECTEINASCIDIN 743","indications":{"approved":[{"status":"approved","condition":"Soft tissue sarcoma","patientPopulation":"Adult, second-line after anthracycline failure"},{"status":"approved","condition":"Ovarian cancer","patientPopulation":"Adult, platinum-sensitive relapsed"},{"status":"investigational","condition":"Pediatric solid tumors","patientPopulation":"Pediatric, refractory/relapsed"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}